In October 2022, the Society for Immunotherapy of Cancer (SITC) released a checklist for running phase 3 cancer immunotherapy combination studies. SITC's aim with these guidelines is to maximize the ...
STK-012 is an α/β biased IL-2 designed to specifically stimulate antigen activated T cells Results from an ongoing Phase 1a/1b to be presented at SITC Company will also present new preclinical data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback